Opendata, web and dolomites

Io-EMP

Tissue-derived acellular micro-scaffold technology reducing or eliminating diabetics’ dependence oninsulin therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Io-EMP project word cloud

Explore the words cloud of the Io-EMP project. It provides you a very rough idea of what is the project "Io-EMP" about.

onset    betalin    lost    mission    cadavers    insulin    environment    extend    chronic    regime    basic    free    cells    immediately    procedure    income    alone    diabetics    transplanted    scaffolds    dependence    scaffold    transplantation    premise    insulinproducing    millions    uncertain    mitigate    eyes    beta    disease    careful    tissue    150    producing    prepare    worldwide    annually    cardiovascular    people    appropriate    17    diabetes    organ    source    stromal    functioning    unstable    pancreas    followed    80    architecture    composition    injecting    life    pancreatic    almost    lifetime    24hrs    death    t1dm    microns    connective    medical    mn    harvested    properly    platform    10    proprietary    cell    naked    eliminate    islet    14    damage    seeded    premature    afflicted    stop    acellular    kidneys    nutrients    with    destruction    nerves    researched    prevent    lifestyle    clusters    therapy    bn    daily    islets    gases    micro    treatment    immunosuppression    preserve    reduce    harvesting    stroma    recipients    autoimmune    70    function    attempt    house    performance    diagnosed    complications   

Project "Io-EMP" data sheet

The following table provides information about the project.

Coordinator
BETALIN THERAPEUTICS LTD 

Organization address
address: 3 MENACHEM BEGIN
city: RAMAT GAM
postcode: 5268101
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.betalintherapeutics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BETALIN THERAPEUTICS LTD IL (RAMAT GAM) coordinator 50˙000.00

Map

 Project objective

Betalin’s mission is to provide a tissue-derived acellular micro-scaffold that will extend the life and the insulin-producing performance of transplanted beta cells in order to reduce or eliminate the dependence of some diabetics on insulin therapy. Type 1 Diabetes is a chronic disease that results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. Its cause is still uncertain and there is no known way to prevent its onset. With~70,000 new cases diagnosed each year, it is estimated that ~17 mn people worldwide are afflicted with T1DM. In the US alone, T1DM results in $14.4 bn in medical costs and lost income annually. Type 1 diabetics face a lifetime regime of insulin therapy and very careful lifestyle management in an attempt to mitigate the long-term complications associated with T1DM such as cardiovascular disease, damage to the eyes, kidneys and nerves, and premature death. In recent years islet transplantation has been researched as a treatment for T1DM. The procedure involves injecting millions of islets (the pancreatic cell clusters that “house” the insulinproducing beta cells) harvested from cadavers, followed by immunosuppression therapy. Islet transplantation is a promising approach but the naked islets are very unstable: they must be transplanted almost immediately after harvesting and up to 80% of the transplanted islets stop functioning within 24hrs. The result is that, after five years, less than 10% of the recipients are free of daily insulin treatment. Betalin’s technology is based on the premise that in order for beta cells to function properly it is necessary to provide an appropriate stromal (connective tissue) micro-environment. The proprietary platform technology is a method to prepare acellular organ-derived micro-scaffolds that preserve the architecture and the basic composition of organ stroma and ensure that no seeded cell will be more than 150 microns from a source of nutrients and gases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IO-EMP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IO-EMP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

NAS (2018)

Nexilis augmentation system

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More